Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes
Purpose There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti‐VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes. Methods A nationwide re...
Gespeichert in:
| Veröffentlicht in: | Acta ophthalmologica (Oxford, England) England), 2017-02, Vol.95 (1), p.28-32 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 32 |
|---|---|
| container_issue | 1 |
| container_start_page | 28 |
| container_title | Acta ophthalmologica (Oxford, England) |
| container_volume | 95 |
| creator | Laugesen, Caroline Schmidt Ostri, Christoffer Brynskov, Troels Lund‐Andersen, Henrik Larsen, Michael Vorum, Henrik Sørensen, Torben L. |
| description | Purpose
There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti‐VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes.
Methods
A nationwide retrospective review of medical records from 2010 to 2013.
Results
We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for diabetic macular oedema. Median follow‐up was 323 days (interquartile range 72–1404 days). Baseline mean visual acuity was 0.57 logMAR (95% CI 0.13–1.01) before injections. After an average of 4.7 injections (range 1–15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13–0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI −0.12 to 0.06). In 12 eyes (36%), visual acuity improved 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0–0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Mean central foveal thickness (CFT) on optical coherence tomography (OCT) scan was 412 μm (95% CI 390–434 μm) before injections. After injections, the mean CFT decreased to 352 μm (95% CI 334–370 μm). The mean reduction in CFT was 14% (95% CI 4–24%, p = 0.01). Sixteen eyes (48.5%) became devoid of oedema on the last OCT scan. Despite the significant reduction in CFT, the visual acuity remained unchanged.
Conclusion
Intravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored. |
| doi_str_mv | 10.1111/aos.13160 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1868308448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4304117641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4870-ded6568119c9f06addef969a66fd379f53cb0d66492bab24b3f7f65c1c58ef53</originalsourceid><addsrcrecordid>eNqNkclKBDEURYMozgt_QAJudNGaVCrTshEnEFyo4K5IJS-QpoY2qWppv95oty4EwbfJg5wcbrgIHVFyTvNcmD6dU0YF2UC7VHI-YVKozZ-dv-ygvZRmhAgqRLmNdgpZSsa03EXPd90QzSIMEUyDo-lCHd7H1tTY9xG7YGoYgsWtsWNjIu7BQWtw6PA8wiL0Y2qW-Ou1Hfo2vIPDsIR0gLa8aRIcrs999HR99XR5O7l_uLm7nN5PbKkkmThwggtFqbbaE2GcA6-FNkJ4x6T2nNmauBxZF7Wpi7JmXnrBLbVcQb7dR6cr7Tz2ryOkoWpDstA0poMcraJKKEZUWap_oIWQTCleZvTkFzrrx9jlf2SKaykKpj-FZyvKxj6lCL6ax9CauKwoqT5bqXIr1VcrmT1eG8e6BfdDfteQgYsV8BYaWP5tqqYPjyvlB41Flx0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859762398</pqid></control><display><type>article</type><title>Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Laugesen, Caroline Schmidt ; Ostri, Christoffer ; Brynskov, Troels ; Lund‐Andersen, Henrik ; Larsen, Michael ; Vorum, Henrik ; Sørensen, Torben L.</creator><creatorcontrib>Laugesen, Caroline Schmidt ; Ostri, Christoffer ; Brynskov, Troels ; Lund‐Andersen, Henrik ; Larsen, Michael ; Vorum, Henrik ; Sørensen, Torben L.</creatorcontrib><description>Purpose
There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti‐VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes.
Methods
A nationwide retrospective review of medical records from 2010 to 2013.
Results
We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for diabetic macular oedema. Median follow‐up was 323 days (interquartile range 72–1404 days). Baseline mean visual acuity was 0.57 logMAR (95% CI 0.13–1.01) before injections. After an average of 4.7 injections (range 1–15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13–0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI −0.12 to 0.06). In 12 eyes (36%), visual acuity improved 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0–0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Mean central foveal thickness (CFT) on optical coherence tomography (OCT) scan was 412 μm (95% CI 390–434 μm) before injections. After injections, the mean CFT decreased to 352 μm (95% CI 334–370 μm). The mean reduction in CFT was 14% (95% CI 4–24%, p = 0.01). Sixteen eyes (48.5%) became devoid of oedema on the last OCT scan. Despite the significant reduction in CFT, the visual acuity remained unchanged.
Conclusion
Intravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/aos.13160</identifier><identifier>PMID: 27473397</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - therapeutic use ; anti‐VEGF ; diabetic macular oedema ; Diabetic Retinopathy - diagnostic imaging ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - physiopathology ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macular Edema - diagnostic imaging ; Macular Edema - drug therapy ; Macular Edema - physiopathology ; Male ; Middle Aged ; Ophthalmology ; ranibizumab ; Ranibizumab - therapeutic use ; Retina - diagnostic imaging ; Retina - pathology ; Retrospective Studies ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - physiology ; Vitrectomy</subject><ispartof>Acta ophthalmologica (Oxford, England), 2017-02, Vol.95 (1), p.28-32</ispartof><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd</rights><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 Acta Ophthalmologica Scandinavica Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4870-ded6568119c9f06addef969a66fd379f53cb0d66492bab24b3f7f65c1c58ef53</citedby><cites>FETCH-LOGICAL-c4870-ded6568119c9f06addef969a66fd379f53cb0d66492bab24b3f7f65c1c58ef53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faos.13160$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faos.13160$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27473397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laugesen, Caroline Schmidt</creatorcontrib><creatorcontrib>Ostri, Christoffer</creatorcontrib><creatorcontrib>Brynskov, Troels</creatorcontrib><creatorcontrib>Lund‐Andersen, Henrik</creatorcontrib><creatorcontrib>Larsen, Michael</creatorcontrib><creatorcontrib>Vorum, Henrik</creatorcontrib><creatorcontrib>Sørensen, Torben L.</creatorcontrib><title>Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes</title><title>Acta ophthalmologica (Oxford, England)</title><addtitle>Acta Ophthalmol</addtitle><description>Purpose
There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti‐VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes.
Methods
A nationwide retrospective review of medical records from 2010 to 2013.
Results
We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for diabetic macular oedema. Median follow‐up was 323 days (interquartile range 72–1404 days). Baseline mean visual acuity was 0.57 logMAR (95% CI 0.13–1.01) before injections. After an average of 4.7 injections (range 1–15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13–0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI −0.12 to 0.06). In 12 eyes (36%), visual acuity improved 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0–0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Mean central foveal thickness (CFT) on optical coherence tomography (OCT) scan was 412 μm (95% CI 390–434 μm) before injections. After injections, the mean CFT decreased to 352 μm (95% CI 334–370 μm). The mean reduction in CFT was 14% (95% CI 4–24%, p = 0.01). Sixteen eyes (48.5%) became devoid of oedema on the last OCT scan. Despite the significant reduction in CFT, the visual acuity remained unchanged.
Conclusion
Intravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>anti‐VEGF</subject><subject>diabetic macular oedema</subject><subject>Diabetic Retinopathy - diagnostic imaging</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Diabetic Retinopathy - physiopathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Macular Edema - diagnostic imaging</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>ranibizumab</subject><subject>Ranibizumab - therapeutic use</subject><subject>Retina - diagnostic imaging</subject><subject>Retina - pathology</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - physiology</subject><subject>Vitrectomy</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkclKBDEURYMozgt_QAJudNGaVCrTshEnEFyo4K5IJS-QpoY2qWppv95oty4EwbfJg5wcbrgIHVFyTvNcmD6dU0YF2UC7VHI-YVKozZ-dv-ygvZRmhAgqRLmNdgpZSsa03EXPd90QzSIMEUyDo-lCHd7H1tTY9xG7YGoYgsWtsWNjIu7BQWtw6PA8wiL0Y2qW-Ou1Hfo2vIPDsIR0gLa8aRIcrs999HR99XR5O7l_uLm7nN5PbKkkmThwggtFqbbaE2GcA6-FNkJ4x6T2nNmauBxZF7Wpi7JmXnrBLbVcQb7dR6cr7Tz2ryOkoWpDstA0poMcraJKKEZUWap_oIWQTCleZvTkFzrrx9jlf2SKaykKpj-FZyvKxj6lCL6ax9CauKwoqT5bqXIr1VcrmT1eG8e6BfdDfteQgYsV8BYaWP5tqqYPjyvlB41Flx0</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Laugesen, Caroline Schmidt</creator><creator>Ostri, Christoffer</creator><creator>Brynskov, Troels</creator><creator>Lund‐Andersen, Henrik</creator><creator>Larsen, Michael</creator><creator>Vorum, Henrik</creator><creator>Sørensen, Torben L.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>201702</creationdate><title>Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes</title><author>Laugesen, Caroline Schmidt ; Ostri, Christoffer ; Brynskov, Troels ; Lund‐Andersen, Henrik ; Larsen, Michael ; Vorum, Henrik ; Sørensen, Torben L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4870-ded6568119c9f06addef969a66fd379f53cb0d66492bab24b3f7f65c1c58ef53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>anti‐VEGF</topic><topic>diabetic macular oedema</topic><topic>Diabetic Retinopathy - diagnostic imaging</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Diabetic Retinopathy - physiopathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Macular Edema - diagnostic imaging</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>ranibizumab</topic><topic>Ranibizumab - therapeutic use</topic><topic>Retina - diagnostic imaging</topic><topic>Retina - pathology</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - physiology</topic><topic>Vitrectomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laugesen, Caroline Schmidt</creatorcontrib><creatorcontrib>Ostri, Christoffer</creatorcontrib><creatorcontrib>Brynskov, Troels</creatorcontrib><creatorcontrib>Lund‐Andersen, Henrik</creatorcontrib><creatorcontrib>Larsen, Michael</creatorcontrib><creatorcontrib>Vorum, Henrik</creatorcontrib><creatorcontrib>Sørensen, Torben L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laugesen, Caroline Schmidt</au><au>Ostri, Christoffer</au><au>Brynskov, Troels</au><au>Lund‐Andersen, Henrik</au><au>Larsen, Michael</au><au>Vorum, Henrik</au><au>Sørensen, Torben L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><addtitle>Acta Ophthalmol</addtitle><date>2017-02</date><risdate>2017</risdate><volume>95</volume><issue>1</issue><spage>28</spage><epage>32</epage><pages>28-32</pages><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Purpose
There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti‐VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes.
Methods
A nationwide retrospective review of medical records from 2010 to 2013.
Results
We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for diabetic macular oedema. Median follow‐up was 323 days (interquartile range 72–1404 days). Baseline mean visual acuity was 0.57 logMAR (95% CI 0.13–1.01) before injections. After an average of 4.7 injections (range 1–15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13–0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI −0.12 to 0.06). In 12 eyes (36%), visual acuity improved 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0–0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Mean central foveal thickness (CFT) on optical coherence tomography (OCT) scan was 412 μm (95% CI 390–434 μm) before injections. After injections, the mean CFT decreased to 352 μm (95% CI 334–370 μm). The mean reduction in CFT was 14% (95% CI 4–24%, p = 0.01). Sixteen eyes (48.5%) became devoid of oedema on the last OCT scan. Despite the significant reduction in CFT, the visual acuity remained unchanged.
Conclusion
Intravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27473397</pmid><doi>10.1111/aos.13160</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-375X |
| ispartof | Acta ophthalmologica (Oxford, England), 2017-02, Vol.95 (1), p.28-32 |
| issn | 1755-375X 1755-3768 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1868308448 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use anti‐VEGF diabetic macular oedema Diabetic Retinopathy - diagnostic imaging Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Female Follow-Up Studies Humans Intravitreal Injections Macular Edema - diagnostic imaging Macular Edema - drug therapy Macular Edema - physiopathology Male Middle Aged Ophthalmology ranibizumab Ranibizumab - therapeutic use Retina - diagnostic imaging Retina - pathology Retrospective Studies Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Vitrectomy |
| title | Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20ranibizumab%20for%20diabetic%20macular%20oedema%20in%20previously%20vitrectomized%20eyes&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Laugesen,%20Caroline%20Schmidt&rft.date=2017-02&rft.volume=95&rft.issue=1&rft.spage=28&rft.epage=32&rft.pages=28-32&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/aos.13160&rft_dat=%3Cproquest_cross%3E4304117641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859762398&rft_id=info:pmid/27473397&rfr_iscdi=true |